Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01635881 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT01635881 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 60 participants.
The verdict
NCT01635881, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
To evaluate the acute safety and device procedural success of the Emerge 1.20 mm PTCA dilatation catheter when used as a pre-dilatation device in the stenotic portion of coronary arteries or bypass grafts.
Interventions
- DEVICE Emerge™ 1.20 mm PTCA Dilatation Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01635881
The ClinicalTrials.gov registry entry for NCT01635881 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Emerge™ 1.20 mm PTCA Dilatation Catheter is the first listed.
NCT01635881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01635881 about?
NCT01635881 is a clinical study titled "Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter". To evaluate the acute safety and device procedural success of the Emerge 1.20 mm PTCA dilatation catheter when used as a pre-dilatation device in the stenotic portion of coronary arteries or bypass grafts.
What is the current status of trial NCT01635881?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2012-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01635881?
The interventions under investigation include: Emerge™ 1.20 mm PTCA Dilatation Catheter (DEVICE).
Who is sponsoring clinical trial NCT01635881?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.